- Home
- RCUS vs BDN Comparison
RCUS vs BDN Comparison
Compare RCUS & BDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- BDN
- Stock Information
- Founded
- RCUS 2015
- BDN 1986
- Country
- RCUS United States
- BDN United States
- Employees
- RCUS N/A
- BDN N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- BDN Real Estate Investment Trusts
- Sector
- RCUS Health Care
- BDN Real Estate
- Exchange
- RCUS Nasdaq
- BDN Nasdaq
- Market Cap
- RCUS 906.4M
- BDN 731.6M
- IPO Year
- RCUS 2018
- BDN N/A
- Fundamental
- Price
- RCUS $8.34
- BDN $4.10
- Analyst Decision
- RCUS Buy
- BDN Hold
- Analyst Count
- RCUS 10
- BDN 1
- Target Price
- RCUS $23.75
- BDN $5.00
- AVG Volume (30 Days)
- RCUS 1.2M
- BDN 2.3M
- Earning Date
- RCUS 08-07-2025
- BDN 07-23-2025
- Dividend Yield
- RCUS N/A
- BDN 13.87%
- EPS Growth
- RCUS N/A
- BDN N/A
- EPS
- RCUS N/A
- BDN N/A
- Revenue
- RCUS $141,000,000.00
- BDN $312,538,000.00
- Revenue This Year
- RCUS N/A
- BDN $57.76
- Revenue Next Year
- RCUS $28.73
- BDN $5.16
- P/E Ratio
- RCUS N/A
- BDN N/A
- Revenue Growth
- RCUS N/A
- BDN N/A
- 52 Week Low
- RCUS $6.50
- BDN $3.41
- 52 Week High
- RCUS $18.98
- BDN $6.54
- Technical
- Relative Strength Index (RSI)
- RCUS 39.01
- BDN 38.62
- Support Level
- RCUS $7.91
- BDN $4.19
- Resistance Level
- RCUS $8.87
- BDN $4.44
- Average True Range (ATR)
- RCUS 0.48
- BDN 0.14
- MACD
- RCUS -0.14
- BDN -0.03
- Stochastic Oscillator
- RCUS 8.24
- BDN 0.00
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About BDN Brandywine Realty Trust
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.